Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

93.48USD
10:50pm IST
Change (% chg)

$-0.28 (-0.30%)
Prev Close
$93.76
Open
$93.70
Day's High
$94.05
Day's Low
$93.27
Volume
792,849
Avg. Vol
2,998,571
52-wk High
$95.42
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

Celgene Corp And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To U.S. FDA
Friday, 5 Apr 2019 

April 5 (Reuters) - Celgene Corp ::CELGENE CORPORATION AND ACCELERON PHARMA ANNOUNCE SUBMISSION OF LUSPATERCEPT BIOLOGICS LICENSE APPLICATION TO U.S. FDA.CELGENE CORP - EMA MARKETING APPLICATION FOR BOTH INDICATIONS PLANNED FOR Q2:19.CELGENE CORP - BLA SUBMISSION INCLUDES BOTH MYELODYSPLASTIC SYNDROMES AND BETA-THALASSEMIA INDICATIONS.CELGENE CORP - COMPANIES ALSO PLAN TO SUBMIT A MARKETING APPLICATION TO EUROPEAN MEDICINES AGENCY IN Q2 OF 2019..  Full Article

Bristol-Myers Squibb And Celgene Received Request For Additional Information And Documentary Materials From FTC
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB - CO, CELGENE RECEIVED REQUEST FOR ADDITIONAL INFORMATION AND DOCUMENTARY MATERIALS FROM FTC.BRISTOL-MYERS SQUIBB - PARTIES UNDERSTAND THAT FTC’S REVIEW IS FOCUSED ON MARKETED AND PIPELINE PRODUCTS FOR THE TREATMENT OF PSORIASIS..BRISTOL-MYERS SQUIBB - REQUEST FOR ADDITIONAL INFORMATION FROM FTC IN CONNECTION WITH THE FTC’S REVIEW OF THE MERGER.BRISTOL-MYERS SQUIBB - BOTH PARTIES CONTINUE TO EXPECT THAT THE MERGER WILL BE CONSUMMATED IN THE THIRD QUARTER OF 2019.BRISTOL-MYERS SQUIBB CO - PARTIES WILL CONTINUE TO WORK COOPERATIVELY WITH THE FTC.  Full Article

Bristol-Myers Squibb Co - Urges Shareholders To Vote "For" Proposed Celgene Transaction On White Proxy Card
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB FILES INVESTOR PRESENTATION HIGHLIGHTING SIGNIFICANT BENEFITS OF PENDING TRANSACTION WITH CELGENE.BRISTOL-MYERS SQUIBB CO - URGES SHAREHOLDERS TO VOTE "FOR" PROPOSED CELGENE TRANSACTION ON WHITE PROXY CARD.  Full Article

Allergan PLC - Robert J. Hugin Appointed To Allergan Board Of Directors
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Allergan plc ::ROBERT J. HUGIN APPOINTED TO ALLERGAN BOARD OF DIRECTORS.ALLERGAN PLC - COMPANY TO RECOMMEND FOR A SHAREHOLDER PROPOSAL TO PHASE IN INDEPENDENT BOARD CHAIR AT NEXT LEADERSHIP TRANSITION.ALLERGAN PLC - HUGIN WAS FORMERLY CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF CELGENE CORPORATION.  Full Article

Obsidian Therapeutics Announces Strategic Collaboration With Celgene
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Celgene Corp ::OBSIDIAN THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH CELGENE TO DEVELOP NOVEL CELL THERAPIES WITH TUNABLE IMMUNOMODULATORY FACTORS, OPENING POTENTIAL FOR CAR-T AND OTHER CELLULAR MEDICINES IN NEW SETTINGS.OBSIDIAN THERAPEUTICS SAYS COLLABORATION INCLUDES AN UPFRONT PAYMENT AND EQUITY INVESTMENT BY CELGENE.OBSIDIAN THERAPEUTICS SAYS COLLABORATION INCLUDES POTENTIAL FUTURE MILESTONE AND ROYALTY PAYMENTS BY CELGENE.OBSIDIAN THERAPEUTICS- ENTER INTO MULTI-YEAR STRATEGIC COLLABORATION WITH CELGENE RECEIVING EXCLUSIVE OPTIONS TO LICENSE CELL THERAPIES.OBSIDIAN - DEAL GIVES CELGENE EXCLUSIVE OPTION TO IN-LICENSE WORLDWIDE RIGHTS FOR CELL THERAPY CANDIDATES THAT INCORPORATE DD-REGULATED IL12 OR CD40L.  Full Article

Biond Biologics Announces $17 Mln Series B Financing
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Celgene Corp ::BIOND BIOLOGICS ANNOUNCES $17 MILLION SERIES B FINANCING.BIOND BIOLOGICS - FINANCING AND DUE DILIGENCE LED BY ISRAEL BIOTECH FUND, HAREL INSURANCE & FINANCE GROUP, WITH PARTICIPATION OF CELGENE, OTHERS.  Full Article

Nantcell Announces New Celgene Investment
Saturday, 5 Jan 2019 

Jan 4 (Reuters) - Celgene Corp ::NANTCELL ANNOUNCES NEW CELGENE INVESTMENT.NANTCELL SAYS SECOND ROUND CROSSOVER FUNDING BRINGS CELGENE'S INVESTMENT TO $105M IN NANTCELL VALUED AT $4 BILLION.  Full Article

Celgene Says $33.5 Bln Fully Underwritten Bridge Facility Obtained From Morgan Stanley And MUFG For Financing Bristol-Myers Squibb Deal
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Bristol-Myers Squibb Co ::CELGENE SAYS $33.5 BILLION FULLY UNDERWRITTEN BRIDGE FACILITY OBTAINED FROM MORGAN STANLEY AND MUFG FOR FINANCING BRISTOL-MYERS SQUIBB DEAL - PRESENTATION.  Full Article

Dragonfly Therapeutics announces expansion of its strategic collaboration with Celgene, doubling the number of programs and including targets for solid tumor indications
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Celgene Corp ::DRAGONFLY THERAPEUTICS ANNOUNCES EXPANSION OF ITS STRATEGIC COLLABORATION WITH CELGENE, DOUBLING THE NUMBER OF PROGRAMS AND INCLUDING TARGETS FOR SOLID TUMOR INDICATIONS.CELGENE - DEAL TO LICENSE INTELLECTUAL PROPERTY RIGHTS TO PRODUCTS DEVELOPED USING DRAGONFLY'S TRINKET TECHNOLOGY PLATFORM FOR A $50 MILLION UPFRONT FEE.  Full Article

Temasek Holdings Dissolves Share Stake In Medtronic, Celgene
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN MEDTRONIC PLC.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN CELGENE CORP - SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN JD.COM BY 27.2 PERCENT TO 5.3 MILLION CLASS A SPONSORED ADRS.TEMASEK HOLDINGS (PRIVATE) LTD TAKES SHARE STAKE OF 596,946 SPONSORED ADRS IN BP PLC.TEMASEK HOLDINGS (PRIVATE) LTD UPS SHARE STAKE IN AC IMMUNE SA BY 95.4 PERCENT TO 2.6 MILLION SHARES.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Deals of the day-Mergers and acquisitions

April 12 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday: